Charles Schwab
IMA

Charles Schwab’s ImageneBio Inc IMA Stock Holding History

Charles Schwab’s Portfolio IMA Stock Details IMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,025
Closed -$20.2K – 3497
2024
Q4 		$20.2K Buy
1,025
+19
+2% +$384 ﹤0.01% 3485
2024
Q3 		$20.9K Hold
1,006
– – ﹤0.01% 3482
2024
Q2 		$19.9K Sell
1,006
-6,156
-86% -$109K ﹤0.01% 3588
2024
Q1 		$122K Hold
7,162
– – ﹤0.01% 3291
2023
Q4 		$169K Buy
7,162
+1,351
+23% +$44K ﹤0.01% 3293
2023
Q3 		$302K Buy
5,811
+756
+15% +$45.5K ﹤0.01% 3211
2023
Q2 		$398K Buy
5,055
+4,049
+402% +$290K ﹤0.01% 3153
2023
Q1 		$41.6K Hold
1,006
– – ﹤0.01% 3379
2022
Q4 		$32.1K Hold
1,006
– – ﹤0.01% 3445
2022
Q3 		$43K Buy
+1,006
New +$58.2K ﹤0.01% 3364
2022
Q2 		– Sell
-5,568
Closed -$408K – 3591
2022
Q1 		$408K Buy
5,568
+273
+5% +$29K ﹤0.01% 3138
2021
Q4 		$797K Buy
5,295
+3,186
+151% +$517K ﹤0.01% 2996
2021
Q3 		$320K Buy
2,109
+212
+11% +$30.8K ﹤0.01% 3254
2021
Q2 		$320K Buy
+1,897
New +$418K ﹤0.01% 3233

Other funds holding IMA

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Charles Schwab's IMA Position: Q1 2025 in Review

Charles Schwab sold out of ImageneBio Inc (IMA) in Q1 2025, closing a stake of 1,025 shares — an estimated $20.2K sold.

Charles Schwab first reported a position in IMA in Q2 2021 and held it in 14 quarters. The position peaked at $797K in Q4 2021. 45 funds tracked by Wall St. Rank hold IMA as of Q1 2025.

  • Charles Schwab reported no remaining ImageneBio Inc position as of Q1 2025 after selling out during the quarter.
  • Charles Schwab sold 1,025 ImageneBio Inc shares in Q1 2025, an estimated $20.2K.
  • Charles Schwab first reported a position in ImageneBio Inc in Q2 2021 and held it in 14 quarters.
  • Charles Schwab's ImageneBio Inc position peaked at $797K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held ImageneBio Inc as of Q1 2025.

Based on Charles Schwab's 13F filing for Q1 2025, filed 9 May 2025.